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I Summary  
This thesis describes and evaluates three animal experiment free approaches for the safety and 
efficacy assessment of pulmonary drug formulation in the pre-clinical phase.  
In the first approach the complex cell culture system MucilAir™ was exposed to pollen through 
the Vitrocell® Powder Chamber to simulate in vitro an allergic reaction and predict drug safety. 
However, cytokine response was not sufficient, and the setup has to be optimized for safety 
studies. Two in vitro setups were further developed for estimating drug safety and inflammatory 
response. For safety studies, an in vitro model should predict human data by using approved 
FDA excipient concentrations. From these excipients the in vitro IC50 was determined with 
pulmonary cell lines and ranked in the thus established SAFE classification. Consequently, 
SAFE allows for predicting human safety data by in vitro testing.  
For estimating potential inflammatory reactions located in the respiratory area, the alveolar cell 
line hAELVi was exposed to the pro-inflammatory cytokines TNF-α and IFN-γ. Similar to an 
inflammatory in vivo reaction, a loss of epithelial barrier function was observed. Furthermore, 
the anti-inflammatory response to hydrocortisone of the stimulated model underlines its poten-
tial for in vitro drug testing.  
The described in vitro models are a promising tool for replacing animal experiments, whereby 





Diese Arbeit beschreibt und bewertet drei tierversuchsfreie Ansätze zur Sicherheits- und Wirk-
samkeitsbewertung von Inhalativa in der präklinischen Phase.  
Im ersten Ansatz wurde das Zellsystem MucilAir™ durch die Vitrocell® Powder Chamber Pol-
len ausgesetzt, um in vitro eine allergische Reaktion zu simulieren. Die Zytokinreaktion war 
jedoch nicht ausreichend und der Aufbau muss für Sicherheitsstudien optimiert werden. Folg-
lich wurden zwei in vitro Modelle entwickelt, um die Arzneimittelsicherheit und Entzündungs-
reaktion abzuschätzen. Für eine Sicherheitsbewertung sollte ein in vitro Modell Humandaten 
unter Verwendung von FDA-Hilfsstoffkonzentrationen vorhersagen. Aus diesen Hilfsstoffen 
wurde der in vitro IC50 Wert für Lungenzellen bestimmt und in die etablierte SAFE-Klassifi-
kation eingestuft. SAFE ermöglicht so die Vorhersage von Humandaten durch in vitro Tests. 
Zur Bewertung von Entzündungen wurden hAELVi Zellen den Zytokinen TNF-α und IFN-γ 
ausgesetzt. Ähnlich wie bei einer entzündlichen in vivo Reaktion wurde ein Verlust der epithe-
lialen Barrierefunktion beobachtet. Darüber hinaus unterstreicht die entzündungshemmende 
Reaktion des Modells auf Hydrocortison sein Potenzial für eine in vitro Sicherheitsbewertungen 
von potenziellen Wirkstoffen.  
Die etablierten in vitro Modelle bieten einen vielversprechenden Ansatz, um Tierversuche zu 
ersetzen, wobei ihre Standardisierung und Validierung künftige Herausforderungen zur Auf-




III Index of Abbreviations 
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State of the art - lung in vitro tools applied in research and industry 
1.1 Overview of the most common lung diseases 
According to the World Health Organisation (WHO) chronic obstructive pulmonary disease 
and lower respiratory infections occupied 3rd and 4th place, respectively, of the most common 
causes of death worldwide.1 The lethality of patients suffering from lung diseases will rise in 
the future due to the COVID-19 pandemic.2 The most relevant lung disorders are summarized 
in Figure 1, divided into four main categories: 1) acute lung diseases e.g., pneumonia and in-
fluenza; 2) chronic inflammatory diseases, e.g. chronic obstructive pulmonary disease (COPD) 
and asthma; 3) occupational lung disorders, such as various forms of lung fibrosis, and 4) paren-
chymal lung diseases, mostly related to immune disorders.3 
 
Figure 1: Overview of the most common lung diseases.  
Lung diseases can be categorized into four main classes according to the lung region affected. The main categorises of adult 
lung diseases are 1) acute diseases, e.g., pneumonia, influenza after infections; 2) chronic inflammatory diseases, e.g., chronical 
obstructive pulmonary disease (COPD), asthma; 3) occupational lung disorders, e.g., pulmonary fibrosis, and 4) parenchymal 
lung diseases, e.g., immune-related lung diseases. Other classes are lung cancer, tuberculosis, and various subtypes of pneu-
monia.3,4 Reprinted from: Shrestha et al. `Lung-on-a-chip: the future of respiratory disease models and pharmacological stud-
ies´, copyright © 2020 critical reviews in biotechnology, Taylor & Francis. 
Chronic lung complications are a cause of underlying diseases mostly because of previous acute 
lung failures such as infections.5 Chronic lung conditions such as asthma and COPD are mainly 
triggered by allergies and an increased inflammatory response due to air contaminations, e.g. 
cigarette smoke and noxious gases.6,7 Acute lung diseases such as pneumonia are caused by 
lower respiratory tract infections of bacteria or viruses8 resulting mostly in acute lung injury 
(ALI) or acute respiratory distress syndrome (ARDS) depending on the symptom severity.9–11 





This diversity of lung diseases leads to an enormous range of treatment options. For example, 
in the ‘Guidelines for the management of adult lower respiratory tract infections' the European 
Respiratory Society (ERS) listed various antibiotic treatment options, e.g., amoxicillin or tetra-
cyclines, depending on the degree and type of infection and recommended that vaccination is 
suitable for risk prevention.12 The Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) compiled a list with medical formulations and typical doses for the pharmacological 
treatment of COPD. Next to inhalable corticosteroids, anticholinergics, beta2-agonists, and var-
ious combinations can be applied via metered dose inhaler (MDI) or dry powder inhaler (DPI) 
to COPD patients.13,14   
Apart from these classic pharmacological treatments, innovative therapies, especially for the 
cure of ARDS due to the spread of COVID-19, are on their way for regulatory approval. At the 
end of 2019, Silva et al. discussed that personalized medicine can offer targeted therapies in-
cluding coordinated treatments for the individual patient´s biochemical and physiological re-
constitution during ARDS.15 In addition, cell therapies with (embryonic) stem cells promise in 
vivo a reconstitution of damaged lung epithelial cells during ALI/ARDS and innovative gene 
therapies can influence protein expression responsible for the regulation of inflammatory sig-
nalling pathways.16 A lot of active pharmaceutical ingredients (API) with potential ARDS treat-
ment options are currently in the pre-clinical phase of drug development. Examples of such 
APIs are common anti-coagulants with effects against vascular dysfunction, immunomodula-
tory pleiotropic and pathway specific consequences (e.g., Elafin and anti-INF-γ therapies), and 
anti-viral agents such as Remdisivir and Favipiravir which have been heavily promoted in their 
development process as treatment for ARDS during the COVID-19 pandemic in 2020.17 A fur-
ther example for an innovative ARDS treatment is the hormone therapy based on PEG-adreno-
medullin submitted as an orphan drug approval by Bayer AG Pharmaceuticals with indication 
for ARDS in clinical phase II.18,19 These drug developments and approvals are essential for new 
therapeutic options to treat the above-mentioned lung diseases. Nevertheless, only a few drug 
candidates pass the long and financially risky drug development process to achieve official 
approval.20 The reasons for the high failure rate are described in the following section. 
1.2 Development of orally inhaled drug formulations 
As soon as a potent drug candidate has been identified, several development phases must be 
passed through. Often, the development process starts with a chemical optimization of the ac-





tive substance molecule, which serves to improve the physiochemical and biological character-
istics to achieve an increased efficacy (lead compound optimization).21 In the pre-clinical phase 
the targeted compound is tested mainly in short-and long term animal studies for toxicology 
and disease-modifying effects.22 A first goal of this testing is the identification of the no-ob-
served-adverse-effect levels (NOAELs) which specify the initial dose for starting the clinical 
phase I.22,23 If there are no safety concerns after the pre-clinical phase, the developing company 
can submit an approval for investigatory new drug (IND) to the US Food and drug administra-
tion (FDA) or clinical trial application (CTA) by the European Medicines Agency (EMA).24 
After authorisation has been obtained from the IND or CTA, respectively, the clinical trials 
start. With an increasing number of participants in the clinical phase, the safety and efficacy of 
the IND is evaluated in humans until the data situation allows for the preparation of a new drug 
application (NDA) which is then sent to the FDA or EMA. An independent advisory committee 
of the agency will discuss the results of the NDA and decide if the drug promises good treatment 
options for the patients.23,25 During the final drug approval phase in Europe the different na-
tional committees can sometimes also be involved in the ultimate approval decision.25 Occa-
sionally, the regular drug approval process can be accelerated due an emergency, like during 
the COVID-19 pandemic, where the BioNTech/Pfizer vaccine received approval after 10 
months, compared to an average of 15 years or longer in the regular approval process.26 More-
over, drug approval processes can be changed when it comes to the approval of orphan drugs 
including a reduced clinical phase II in 4 years compared to 6 years for standard approv-
als.25,27,28 Figure 2 summarizes the drug development process which must be passed for a final 
FDA approval. 






Figure 2: Overview of the drug development and approval process of new drugs by the FDA.  
An investigational new drug (IND) undergoes during their development various phases of pre-clinical research and clinical 
studies. After a successful synthesis and purification, the IND will be tested in the pre-clinical phase for their efficacy and 
safety by inter alia short- and long-term animal studies followed by an official IND submission. Passing the three phases of 
clinical studies, the advisory committees decide for an approval of the drug product.23 Reprinted from: ̀ New Drug Development 
and Review Process´, copyright © 2020 FDA homepage, https://www.fda.gov/drugs/cder-small-business-industry-assistance-
sbia/new-drug-development-and-review-process, accessed 01/03/2021.  
A key element during the drug development process is the IND application, which is crucial for 
the start of clinical studies in humans. It stands to reason that potential safety issues of a new 
drug should be clarified in advance. This is done in IND enabling studies which cover the pre-
clinical safety assessment by a complete description of the pharmacodynamics- and kinetics 
(ADME properties), safety pharmacology, reproductive and developmental toxicity, as well as 
genotoxicity studies.29 The FDA provides various forms which must be submitted for IND ap-
plication. One of the most important forms is the FDA 1571 Title 21, Code of Federal Regula-
tions (CFR) Part 312 including a detailed description of the data situation in the pre-clinical 
evaluation.29–32 To ensure FDA acceptance of the data integrated in an IND application inter-
nationally accepted good laboratory and manufacturing practice (GLP/GMP) and quality guide-
lines from the `Organisation for Economic Co-operation and Development´ (OECD) and the 
`International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use´ (ICH) should be met.33–35  
 
 





1.3 Regulatory requirements for safety assessment for pharmaceuticals and chemicals  
The ICH, a consortium of key players from regulatory authorities and pharmaceutical indus-
tries, has established standards on quality, safety, efficacy, and also provides the multidiscipli-
nary guidelines, all of which help to unify the international drug development process.36 These 
guidelines ensure that adequate data quality can be guaranteed, which makes a successful drug 
approval more likely. The ICH guidance document M3 (R2), for example, describes in detail 
the required data for the pre-clinical evaluation of pharmaceuticals to support subsequent clin-
ical trials.37,38 Safety assessments do not only play an essential role during drug approvals, they 
are also important in the registration and market authorization of chemicals and, consequently, 
their commercial distribution and industrial processing.39 Sufficient data is important in order 
to obtain a European market approval for chemicals. Therefore, the European Union’s REACH 
regulation ((EC) 1907/2006) legally regulates the market and safety of chemicals since 2007. 
According to the slogan: 'no data, no market', chemical manufacturers must provide all neces-
sary data for a detailed safety evaluation for the product that they want to release to the market.40 
The best way for a uniform evaluation of the product is to adhere to certain guidelines. Relating 
thereto, the OECD, an international association with 36 member states aiming for the reduction 
of economic, political, and environmental complications through standardized procedures, is 
responsible for the development of such guidelines.41 The internationally accepted OECD 
guidelines include the (bio)safety assessment of chemicals and the protection of the environ-
ment and human health. This collection of guidelines for the testing of chemicals is divided into 
5 sections, (1) physical-chemical properties; (2) effects on biotic systems; (3) environmental 
fate and behaviour; (4) health effects and (5) other test guidelines.42 The 4th section of chemical 
testing, which deals with health effects, is relevant for this dissertation and will be discussed 
below in more detail. In this selection of guidelines, 80 OECD regulations describe suitable 
methods for identifying potential health risks of the substances under test. For example, the 
(acute) toxicity, genotoxicity, neurotoxicity, sensitization and corrosion effects of the test sub-
stance are addressed in vitro and in vivo studies depending on the organ affected.43 Many in 
vitro assays are officially accepted, especially the in vitro skin evaluations, such as the skin 
sensitization test (No. 442 C-E) and the in vitro skin irritation test (No. 439), and also many in 
vitro genotoxicity tests, as the mammalian cell micronucleus test (No. 487). However, no in 
vitro method for the inhalative safety assessment is yet recommended by the OECD. Conse-
quently, the required data must be generated by animal experiments. The official guidelines for 
the applied in vivo methods are No. 403, 433 and 436, reporting the acute toxicity, and the 





guidelines No. 412 and 413, analysing the sub-acute and sub-chronical effects to the lung after 
substance exposure (Table 1).  
Table 1: OECD Guidelines for the inhalative safety assessment of chemicals performed by in vivo studies. TG No.: Test 
guideline number; LC50: Lethal concentration; GHS: Globally Harmonized System; BMC: Benchmark concentration;  
NOAEC: No observed adverse effect concentration; LOAEC: Lowest observed adverse effect concentration.  
TG No. Indication Aim Instruments Reference 
Acute Toxicity 
403 
Acute inhalation  
toxicity, 4 h 




Fixed Concentration  
Procedure, 4 h 








step wise to GHS 
Inhalation chamber 





repeated dose  
inhalation toxicity, 
28-day study 
quantitative risk  
assessments 
BMC, NOAEC, LOAEC 
Inhalation chamber 








quantitative risk  
assessments 
BMC, NOAEC, LOAEC 
Inhalation chamber 




In order to adequately comply with the law and, thus, ensure safety for humans and the envi-
ronment, animal experiments cannot be avoided.49 Animal experiments are essential, especially 
for the inhalation safety assessment, because, as mentioned above, no alternative methods are 
available of yet.50   
Animal experiments are very expensive, in some cases ethically unacceptable, and they often 
produce results that are not valid enough to predict potential safety issues in humans.51,52 In 
2011, 1.3 billion € were spent on animal experiments for the safety assessment of chemicals in 
total, whereby the acute inhalation toxicity is calculated with 13.85 million € and sub-chronic 
toxicity studies with 61.95 million €.53 Next to these considerable costs the predictivity of ani-
mal experiments is called into question by numerous studies. Only 71% of two-species studies 
can predict the human toxicity studies54 resulting in a 89% failure rate of new drugs after human 
clinical trials.51 Reasons for this low predictivity are physiological differences between the spe-





cies that lead to, among other things, diverse metabolism functions, varied microbiome consti-
tutions, altered gene expression profiles and differently expressed disease phenotypes.54 In re-
sponse to these limitations of animal experiments, the demand for suitable in vitro methods is 
increasing. The preference of animal-free research was expressed for the first time in 1959 by 
Russel and Burch, who, in their publication ‘The Principles of Humane Experimental Tech-
nique’, proclaimed the Three Rs principle to refine, reduce and replace animal experiments.55 
These principles have not lost their validity, legitimacy and importance to this day and have 
established themselves as a fundamental ethical concept in science.56 As a result of the imple-
mentation of the Three Rs principle, Figure 3 highlights the increasing demand of in vitro assays 
in the pharma industry. Goh et al. calculated all in vitro assays performed in the main three 
fields genotoxicity, safety pharmacology and ADME of pre-clinical studies from three pharma 
companies and three contract research organisations (CRO) in the years 1980 to 2013 with the 
result that the percentage of performed in vitro assays in the pharma industry has increased by 
a remarkable 20% since 2012.57  
 
Figure 3: Increasing number of in vitro tests from 1980 – 2013 in three CRO (contract research organisations) and three 
pharma companies. The total amount of performed in vitro tests per year was normalised to the amount of all in vitro test 
applied from 1980 – 2013 and multiplied by 100 to obtain the percentage. Reprinted from: Goh et al. `Development and use of 
in vitro alternatives to animal testing by the pharmaceutical industry 1980-2013´; copyright © 2015 Oxford University Press.57 
There is also increasing public pressure to reduce animal testing. A prime example of such a 
successful political implementation is the development of the in vitro safety assessment of 
chemicals, especially for toxicological studies, in the cosmetics industry.58 The regulation (EC) 
No 1223/2009 of the European Parliament and of the Council, which came into force on No-
vember 30, 2009, states that animal experiments for testing finished cosmetics are forbidden by 
law.59,60 This law exerts pressure on research and industry to focus on developing alternative 
methods for testing. On December 12, 2013, the European Union Reference Laboratory for 





Alternatives to Animal Testing (EURL ECVAM) recommended the Direct Peptide Reactivity 
Assay (DPRA) testing to evaluate potential skin sensitizers.61 The methods for in vitro evalua-
tion of skin sensitizer was expanded to the cell-based assays KeratinoSens™, LuSens, h-CLAT, 
(m)MUSST showing a better predictivity to human data.62 Urbisch et al. show that in silico 
methods as the QSAR (Quantitative structure–activity relationship) Toolbox and TIMES (tissue 
metabolism simulator) were more reliable to identify skin sensitizer in comparison to the in 
vivo LLNA (local lymph node assay).63 In 2018, the ECHA (European Chemical Agency) rec-
ommended how to use the established in vitro skin sensitizing methods within the safety as-
sessment to meet the REACH regulation according the OECD guidelines 442 C-E.64 Although 
the in vitro assays for examining the skin sensitizer were successfully established in guidelines, 
no officially OECD recommendations are available for most other parts of toxicological studies 
of chemicals such as orally inhaled substances. To steer this development towards the develop-
ment of applicable animal-free alternatives, the OECD published the 'Guidance Document on 
Good In Vitro Method Practices (GIVIMP)´ in 2018. In these guidelines detailed recommen-
dations regarding the most important aspects of an in vitro assay are made, including, for ex-
ample, quality considerations, devices, test systems and reporting of the results.65 These re-
quirements are important to consider during the development of new in vitro test systems for 
the safety assessment of orally inhalable substances and drugs. Following these requirements, 
an effective and targeted establishment for the development of an officially recognized guide-
line can succeed. The state of the art in research and industry in developing a valid alternative 
method for the safety assessment of orally inhaled substances will be summarized below. 
  





1.4 In vitro systems for orally inhaled drug products in research and industry 
For an in vitro simulation of the lungs, countless well-established test systems are available. 
They differ in their complexity from simple monolayer 2D cultures to mixed cultures (co-cul-
tures), 3D cultures and overly complex co-cultures with more than three cell types. The costs 
of these test systems increase but the 
physiological relevance grows as well 
(Figure 4). But none of the test systems is 
validated under permitted guidelines rec-
ommended from the OECD or ICH.66 A 
complete validation of an applicable in 
vitro method implies a successful transfer 
from research to industry.66,67 The coor-
dination of this validation process is car-
ried out by the US Interagency Coordi-
nating Committee on the Validation of 
Alternative Methods (ICCVAM)68 and, for the European Union, by the EURL ECVAM.69 In 
the ECVAM status report from 2019, only two alternatives for respiratory in vitro alternatives 
are reported: 1) the in vitro system ALIsens, which should replace the respiratory LLNA assay, 
and 2) undergoing validation at the time of publication, the EpiAirway™ system, a recon-
structed human lung epithelium for detecting acute inhalation toxicity studies.70   
The question arises why, so far, only a few lung in vitro systems and simulations were estab-
lished in research and industry. The main challenges for the development of in vitro methods 
are the simulation of the human respiratory physiology, the dosimetry of inhaled particles and 
mechanism of acute toxicity including the adverse outcome pathways (AOP).71 Figure 5 A de-
scribes the airflow of inhaled gas particles, whereby a very abrupted and spontaneous direc-
tional change with increased deposition by impaction and sedimentation appears in the upper 
airways. The mild deposition forms diffusion and electrostatic interaction are present in the 
alveoli. The flow of inhaled gases depends on the diameter of the airway, in other words, larger 
airways result in a higher turbulence, and a laminar flow occurs in smaller animals considering 
the same velocity.71,72 Figure 5 B illustrates the concentration of inhaled particles on their way 
through the respiratory system. The concentration of the particle is decreased stepwise by their 
interaction with the tissue barriers mucus and epithelial layer and the diffusion and metabolism 
from the basal cells and the submucosa in the blood. The transport of particles and gas is mainly 
Figure 4: Overview of available in vitro models of the respiratory 
system starting from simple 2D cultures to ex vivo models. With 
the increase in complexity, the costs rise, but also the physiological 
relevance. Reprinted from Lacroix et al. `Air-Liquid Interface in 
Vitro Models for Respiratory Toxicology Research: Consensus 
Workshop and Recommendations´, copyright 2018 Applied In Vitro 
Toxicology.66 





dependent on convection, diffusion, absorption, dissolution, and possible chemical reac-
tions.71,73 
 
Figure 5: Illustration of complex physiological parameters and deposition mechanisms of potential inhaled substance 
deposition in the lung. (A) The airflow coming from the upper airways underlies spontaneous direction changes and an in-
creased speed. The particle deposition is mainly characterized by impaction and sedimentation and in the alveoli by diffusion 
and electrostatic precipitation with mild directional changes at low air velocity. (B) Concentration depended on change of an 
inhaled chemical in gas phase by passing the sections (Airway, lung tissue, and blood). Cin = concentration of inhaled gas, Cout 
= concentration of exhaled gas if no metabolism took place, Cgi/Cit = concentration of gas at the interface to mucus/ epithelial 
layer, C1/C2 = concentration in mucus/epithelial cells, Cn-1/Cn= concentration in submucosa/blood. Adapted from: Clippinger 
et al. `Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data re-
quirements: An international workshop report´, copyright © 2018 The Authors. Published by Elsevier Ltd., original published 
from Bogdanffy et al. 1999 and US EPA 1994.71–73 
In addition to the physiological parameters and the deposition mechanism of substances in the 
alveolar space, the cellular constitution and the interactions of various cell types are also diffi-
cult to simulate in vitro. The alveolar region consists of two epithelial cell types: alveolar type 
1 (AT1) cells which, together with capillary endothelial cells, form the air blood barrier, and 
alveolar type 2 (AT2), the surfactant producing cells.74 In the upper alveoli, the protein as well 
as mucus producing club (clara cells) and goblet cells are located.75 Next to these cells, alveolar 
macrophages, two types of mast cells, fibroblasts (lipofibroblasts, myofibroblasts, alveolar fi-
broblasts) are responsible for a functional human alveolus.76,77 The lungs of humans and mice 
differ in their respective number of pulmonary lobes (mice have only one on the left side), and 
in the constitution of the bronchioalveolar duct junction where mainly club and bronchoalveolar 
stem cells (BASC, involved in injury-induced cellular plasticity) are present (Figure 6).76 






Figure 6: Cellular composition of human (A) and mouse (B) lung with their corresponding cell types.   
(A) Structure of human lung. The grown human lung consists of two epithelial cell types: alveolar type 2 (AT2) surfactant 
producing cells and the alveolar type 1 (AT1) cells which are responsible for the gas exchange, forming the air blood barrier. 
In the upper alveoli, club and goblet cells are located. Next to these cells, alveolar macrophages, two types of mast cells, 
fibroblasts (lipofibroblasts, myofibroblasts, alveolar fibroblasts) are responsible for a functional human alveolus. (B) Structure 
of mouse alveoli. The alveolar region consists of two subsets of AT2 cells (Axin2+ AT2) with high stem cell activity. The 
epithelium between the bronchioles and the alveoli is named bronchoalveolar duct junction and consist of bronchoalveolar 
stem cells (BASCs); the basal cells are limited to the trachea and the bronchi. Cells with no complete border are not fully 
confirmed. Adapted from: Evans and Lee `Alveolar wars: The rise of in vitro models to understand human lung alveolar 
maintenance, regeneration, and disease´, © 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by 
Wiley Periodicals LLC on behalf of AlphaMed Press.76 
Despite this challenge of intricacy, in vitro lung models have evolved through several stages of 
development over the past few years. Table 2 summarizes in vitro models with increased com-
plexity predominantly of the deep lung area. The list starts with simple monolayer cultures of 
available epithelial cell lines, like Calu-3, A549, the human alveolar primary cells (hAEpC) 
with Type II and Type I characteristics and the hAELVi (human alveolar lentivirus immortal-
ized) cells.78–85 However , the predictability for in vivo outcomes of frequently used monolayer 
cells of in vitro lung models, especially the simulation of kinetic absorption and permeation, is 
still up for discussion.86 To increase the predictability, epithelial cells can be co- or even triple 
cultivated with immune cells (THP-1, monocyte derived macrophages (MDM)) and human 
pulmonary microvascular endothelial cells (HPMEC) to simulate the air-blood barrier.87–92 Be-
cause the lung is constituted of many cellular and non-cellular (mucus, surfactant) barriers, 
whose spatial arrangement is essential for a functioning lung physiology, lung organoids were 
developed. Organoids are defined as 3D in vitro tissue structures simulating a complete in vivo 
organ.93,94 Most organoids were cultivated in a Matrigel matrix and are mostly generated from 
hPSC (human pluripotent stem cells).95–98 The main limitation of organoids is the low stand-
ardisation of cell cultivation due to the complicated differentiation protocols with countless 





variations, which causes high costs.99 Lung-on-a-chip models provide the cell cultivation in a 
microfluidic device. With a dynamic flow for media transport a simulation of the function and 
exposure scenarios of the different lung areas is possible depending on the integrated cell types. 
However, this technology is still in its infancy.4,100–102 A further development of complex in 
vitro lung systems are the 3D tissue cultures, which are commercially available, for example 
from MatTek and Epithelix. These systems include ciliated cells, goblet cells with a mucus 
layer and basal cells in the variant for the upper airways (MucilAir™, Epithelix) or the lower 
airways (SmallAir™, Epithelix), mucuciliary epithelium on fibroblasts (EpiAirway, MatTek), 
or the 3D constitution of alveolar epithelial cells, fibroblasts and alveolar endothelial cells (Epi-
Alveolar™, MatTek).103–106 The overall advantage of these ready-to-use systems is the high 
degree of standardization which is demonstrated by their presence in the ECVAM validation 
process (EpiAirway™) as mentioned above.70 Further advantages of these systems are the in-
dividual user adaption through various cells (e.g. immune cells), the availability of diseased 
models as well as the combination with innovative exposure systems.107 One of the most re-
nowned manufacturers of exposure systems for inhalation toxicology is VITROCELL®Sys-
tems. These VITROCELL® devices can expose airborne particles or chemicals (gases, mix-
tures, NPs) to many formats of cell cultures cultivated in liquid-liquid interface (LLI) or in air-
liquid interface (ALI).108 In 2019, Kooter et al. investigated asthma patients’ increased sensi-
tivity to copper oxide nanoparticle aerosols using the MucilAir™ (Epithelix) and a VITRO-
CELL® exposure system. They observed a changed response of the model in a diseased state 
after NP exposure in comparison to the healthy cells by performing a transcriptomic analysis.109 
This experimental set up tries to simulate the particle concentration in the atmosphere more 
realistically than the calculation of particle concentration in dilution (LLI).110   
Nevertheless, there are still limitations to the advanced complex exposure experiments, such as 
technical restrictions to simulating the highest dose of airborne particles and substances com-
pared with surrounding contaminant concentration.111 Future challenges for the standardisation 
of physiologically relevant exposure systems with ALI cell cultures are the validation of in vitro 
to in vivo outcomes, simulation of chronical exposure and the evaluation of the dosimetry (gas 
versus particles) to identify the exact NOAEL/LOAEL.111,112  
These challenges were discussed during an international workshop with respiratory toxicology 
experts in 2018, which evaluated the necessary conditions and set-up for an in vitro test system 
for respiratory safety assessment aiming the ECVAM validation. During the discussion, the 
main question arose as to which results can be validated to which endpoints regarding, for ex-





ample, respiratory irritation, sensitization, or inflammation. The problem being that no stand-
ardisation of the established in vitro methods is possible, and, most critically, in vitro models 
are not compared to human clinical data and only correlated to animal data.66 Based on these 
challenges, further experimental approaches and additional data will result from this thesis, 
which are required for the improvement and optimization of the respiratory in vitro models. 
This contributes to the target achievement of a valid in vitro test system and a wide-reaching 
implementation of the Three Rs principle in research and industry. 
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Table 2: Examples of in vitro systems with increasing complexity, simulating mainly the deep lung area, categorized in monolayer, co-culture, triple-culture, organoids, lung-on-a-chip 
models and 3D tissue models.  
Abbreviations: AT I/AT II: alveolar epithelial cells type I/II; LLC: Liquid-liquid conditions; ALI: Air-liquid conditions, ATCC: American type culture collection; DSMZ: German Collection of 
Microorganisms and Cell Cultures; PADDOCC: Pharmaceutical Aerosol Deposition Device On Cell Cultures; hAELVi: human alveolar epithelial lentivirus immortalized; hAEpC: human alveolar 
epithelial cells; hPSCs: human pluripotent stem cells; hPAEC: human Pulmonary Artery Endothelial Cells AM: Alveolar macrophages; MDM: monocyte derived macrophages; MDDC: monocyte 
derived dendritic cells; NPs: nanoparticles; MWCNTs: Multi-walled carbon nanotubes; FACS: Fluorescence activated cell sorting; PAHs: polycyclic aromatic hydrocarbons; CBF: cilia beating 
frequency.  
 Title of in vitro system 
Cultivation/ 
Exposure system 





Rat AT I epithelial cells LLC 
Barrier function 
> 1000 Ω⸱cm² 
No [78] 
Human lung adenoma carcinoma 
cells A549 
(AT II like) 
ALI, Transwell™ 
Endocytic ability, 









> 2000 Ω⸱cm², permeability 
No [81] 










Immortalized cell line, barrier properties 
> 1000 Ω⸱cm², permeability 




Stem cell derived, wound healing, barrier 
properties > 200 Ω⸱cm² 
No [85] 
Co-Culture 




Isolated from rat lung, transport studies No [87] 
Primary human alveolar cells 




Barrier properties < 1000 Ω⸱cm², deposi-
tion NPs, inflammation 
No [88,89] 




Permeability, barrier properties 





A549/ 16HBE14o/ hAEpC + 
MDM + MDDC 
LLC, 
Transwell™ 
Comparison to primary cells hAEpC, bar-
rier properties A549 
> 200 Ω⸱cm², 16HBE14o/ hAEpC 
> 1000 Ω⸱cm² 
No [91] 
NCI-H441 cells +  
HPMEC-ST1.6R cells +  
THP-1M 
ALI, Transwell™ 
Permeability, barrier properties 
< 100 Ω⸱cm², Inflammation (IL-8) 
No [92] 





 Title of in vitro system 
Cultivation/ 
Exposure system 
Short description Commercially available Reference 
Organoids 
Generated from hPSCs  
(lung bud) 
Matrigel 
Histology, differentiation marker, fluo-
rescence microscopy 
No [95] 
Mice AT II, human AT II Matrigel 
Histology, differentiation marker, immu-
nofluorescence, FACS 
No [96] 
Human AT II Matrigel 
Histology, differentiation marker, fluo-
rescence microscopy, virus exposition 
No [97] 







Calu-3 Chip device 
Cigarette smoke, Viability, mucus stain-
ing, Permeability, inflammation 
No [100] 
16HBE14o− cells + pHPAEC + 
pHUVEC 
Chip device, dynamic 
exposure 
Permeability, viability, inflammation, im-
munofluorescence 
No [101] 
Primary hAECs, neutrophiles 
Chip device, dynamic 
exposure 
Permeability, immunofluorescence, adhe-
sion, SEM/TEM, inflammation, gene ex-
pression 
No [102] 
3D Tissue models 
MucilAir™ ALI, Transwell™ 
PAHs exposure, viability, gene expres-
sion, barrier properties 




SmallAir™ ALI, Transwell™ 
Histology, CBF, no mucus production, 

















cence, TEM, barrier properties 
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2 Aims of the thesis 
The main goal of this thesis is to establish an in vitro test strategy respecting the Three Rs 
principle to reduce animal experiments in drug development processes in research and industry. 
Therefore, this dissertation aims at developing an in vitro model for safety and efficacy testing 
of orally inhalable drug products for which no official test guideline is yet available. In addition, 
this thesis wants to provide an understanding of the advantages and disadvantages of in vitro 
methods with a discussion focused on the acceptance of such models in officially approved 
guidelines for perspective inhalative therapies. Therefore, a three-step approach is proposed, 
pursuing three major aims are: 
1. The first study combined complex in vitro methods which should provide information about 
the advantages and disadvantages of a more physiological experimental setup. By recognizing 
possible deficiencies in this initial work, the following studies could be set up more target ori-
ented. 
2. In a second study, a more simplified method was able to provide an improved correlation 
with a human data set focussing on acute toxicity. By obtaining valuable results, an in vitro 
classification system for approved excipients was established.  
3. As a final study, the inflammatory reactions of the alveolar epithelium could be simulated by 
a simplified experimental set-up. This inflammation model can be used for the in vitro testing 
of not currently approved anti-inflammatory/inflammatory substances and drug products in fu-
ture.  
 




3 Major outcomes of the thesis – Extended summary 
This thesis aims at establishing a suitable in vitro test strategy based on various approaches, 
which can be standardized and be valid enough to support prospective guidelines. 
Therefore, the first approach attempts to simulate a physiological scenario in vitro using a more 
complex experimental design. In addition, an ointment formulation was applied to investigate 
if the test system can be used to evaluate an anti-inflammatory effect. The ointment is intended 
for reducing pollen exposure by applying it to the human nasal mucosa.  
To simulate the physiological exposure in vitro, the cell culture system MucilAir™ was used 
under air-liquid conditions and was placed as an insert in the Vitrocell® Powder Chamber 
(VPC). The VPC enables the targeted exposure of pollen (Iva xanthiifolia) on MucilAir™ 
which was treated beforehand with the ointment formulation. After exposure, the pollen pene-
tration was determined with the aid of confocal scanning microscopy (CLSM) and the cytokine 
release of TNF-α, IL-6 and IL-8 was measured.  
It turned out that the ointment formulations should be regarded as a protective layer on the 
MucilAir™ system. Therefore, no increased cytokine release could be measured in comparison 
to the LPS control.  
However, the results of this study could not be compared with in vivo data since the cytokine 
release was not sufficient and no adequate human data sets were available. In addition, the 
experimental design had disadvantages, such as the undefined amount of exposed pollen, lack 
of cell viability measurements, the indefinite thickness of the ointment layer on MucilAir™ and 
the poor quantity of data.  
Due to this lack of standardization and validation, the question was considered whether a re-
duced method complexity in a first evaluation level would be more target oriented. Therefore, 
in the subsequent study, the focus was only on the cytotoxicity.  
The second study presented in this thesis aimed at correlating in vitro data to human in vivo 
data based on the cytotoxicity as standalone parameter. Therefore, the safety assessment of 
excipients (SAFE) classification was developed to link data of human epithelial cells to ap-
proved FDA concentrations for orally inhaled drug products.  
The SAFE system includes the in vitro calculated IC50 values obtained by a standardised cell 
viability measurement (MTT assay) after the exposure of 23 excipients to A549 and Calu-3 
monolayer cells. The resulting IC50 values were correlated with the approved FDA concentra-
tions of these excipients. A threshold of 0.1% (1 mg/mL) separates four safety classes, which 




allows a categorisation by the resulting IC50 values. The hazard potential of a substance in-
creases with the ascending classification class.   
The SAFE classification provides an opportunity to classify components of potential drug for-
mulations in vitro based on the IC50 values. Two aspects can be clarified by applying the SAFE 
approach. On the one hand, potential high toxicity of a substance can be excluded directly be-
fore the costly development process starts, and, on the other hand, if future in vitro testing is to 
be preferred, a suitable concentration range can be evaluated in which cell compatibility is en-
sured. Nevertheless, one single parameter is not sufficient to provide a safety assessment of a 
drug component. Therefore, the final study extended the test strategy to the inflammatory con-
sequences after substance exposure. 
The ongoing COVID-19 pandemic demonstrates how inflammatory lung diseases can dramat-
ically increase over a short period of time. So, in the third and last part of this thesis, an in vitro 
inflammation model was developed to show fast and reliable anti-inflammatory effects of po-
tential drug products to provide treatment options for inflammatory lung diseases relatively 
quickly, if needed.  
For this purpose, a monolayer cell system was developed using an innovative cell line, the 
human Alveolar Epithelial Lentivirus immortalised (hAELVi) cells. After a stimulation with 
the pro-inflammatory cytokines TNF-α and IFN-γ, the hAELVi showed typical inflammatory 
reactions of the epithelium, such as a decreased barrier property indicated by a low transepithe-
lial electrical resistance (TEER) < 500 Ω x cm² and an increased permeability of the cells with 
a calculated apparent permeability coefficient (Papp) of 9.30 x 10
–6 cm/s by monitoring the tracer 
molecule sodium fluorescein. In addition, the supplementation of hydrocortisone (HC) in the 
cell culture media did not allow any significant inflammatory reaction. Due to the high quantity 
of the data obtained in this study, a critical TEER value of 245 Ω x cm² could be calculated 
using a reciprocal linear fit. Reaching this value, e.g., by a possible substance exposure or cy-
tokine stimulation, a significant inflammation of the cells due to a loss of barrier function and 
an increased sodium fluorescein permeability can be observed. A treatment of the inflamed 
hAELVi cells with potential anti-inflammatory inhalable therapies can be used for the in vitro 
safety and efficacy assessment in further studies.   
In this dissertation no standardized and officially accepted in vitro test strategy could be devel-
oped. However, it became clear that a promising approach to developing a safety assessment 
follows a stepwise procedure. This includes first the investigation of cytotoxicity by applying 




the SAFE classification, which is followed by the inflammatory testing using the hAELVi in-
flammation protocol resulting in a more complete picture of the consequences of a substance 
exposure. Further studies should integrate more potential cellular targets, for example, an in-
creased ROS production or a changed protein modification, which could have harmful effects 
on the entire organism. Another important future development aspect is the optimisation of 
experimental conditions implementing co-culture systems under air-liquid cultivation to in-
crease the predictability of in vitro systems.
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List of abbreviations used: HC = hydrocortisone; FCS = fetal calf serum; TNF- = tu-
mour necrosis factor-alpha; INF- = interferon-gamma; TEER = transepithelial electri-
cal resistance; SAGM = Small Airway Epithelial Cell Growth Medium™ 
 
 
Figure S1. Light microscopy images of hAELVi cells cultured in SAGM without 




Light microscopy images of: (a) an unstimulated hAELVi cell control, showing regular 
cell morphology on Transwell inserts; (b) hAELVi cells stimulated with combined 25 
ng/ml TNF- and 30 ng/ml INF-, showing a changed morphology in comparison to the 
unstimulated control (the cells were rounder in shape and showed the first morpholog-
ical signs of apoptosis). These cells were cultured in the absence of HC and FCS. It 
should be noted that hAELVi cells cultured +HC/+FCS and +HC/–FCS did not show 
any morphological anomalies, either before or after cytokine stimulation. 
  




Figure S2. Light microscopy images of hAELVi cells cultured in SAGM with HC 




Light microscopy images of: (a) an unstimulated hAELVi cell control, showing regular 
cell morphology on Transwell inserts; (b) hAELVi cells stimulated with combined 25 
ng/ml TNF- and 30 ng/ml INF-, which did not affect the morphology of the cells. 
These cells were cultured in presence of HC, and the absence of FCS. 
 





Light microscopy images of: (a) an unstimulated hAELVi cell control, showing regular 
cell morphology on Transwell inserts; (b) hAELVi cells stimulated with combined 25 
ng/ml TNF- and 30 ng/ml INF-, which did not affect the morphology of the cells. 
These cells were cultured in presence of HC and FCS. 
 




Figures S4–S8 show the TEER of hAELVi cells according to the different passages, 
and in culture conditions (with and without HC and FCS). When considering the change 
in TEER values over the hAELVi cell culture period, it becomes obvious that the TEER 
values reached and the temporal generation of the cell barrier varies significantly, 
which can be attributed to both the addition of HC and effect of the passage number. 
 
Figure S4. Passage-dependent change in TEER over an extended culture period, 




The TEER was measured three times a week followed by a medium change. When a 
TEER of up to 1000 ·cm2 was reached, the cells were stimulated with TNF- (50 
ng/ml and 17 ng/ml in the apical and basolateral compartments, respectively). In pas-
sage 29 (p29) and passage 41 (p41), stimulation with TNF- was performed on day 
14; passage 34 (p34) was stimulated on day 7 (indicated by the dotted line). The TEER 
was measured 24 and 48 hours after stimulation. n = 6 wells for the control group and 
n = 6 wells for the stimulation group. 
 
Figure S5: Passage-dependent change in TEER over an extended culture period, 




The TEER was measured three times a week followed by a medium change. When a 
TEER of up to 1000 ·cm2 was reached, the cells were stimulated with TNF- (50 
ng/ml and 17 ng/ml in the apical and basolateral compartments, respectively). In pas-
sage 29 (p29) and passage 34 (p34), stimulation with TNF- was performed on day 
14; passage 41 (p41) was stimulated on day 5 (indicated by the dotted line). The TEER 




was measured 24 and 48 hours after stimulation. n = 6 wells for the control group and 
n = 6 wells for the stimulation group. 
 
Figure S6. Passage-dependent change in TEER over an extended culture period, 




The TEER was measured three times a week followed by a medium change. When a 
TEER of up to 1000 ·cm2 was reached, the cells were stimulated with 25 ng/ml TNF-
 and 30 ng/ml IFN-. In passage 31 (p31) and passage 33 (p33), stimulation was 
performed on day 13; passage 35 (p35) was stimulated on day 7 (indicated by the 
dotted line). The TEER was measured 24 and 48 hours after stimulation. n = 3 wells 
for the control group and n = 3 wells for the stimulation group. 
 
  




Figure S7. Passage-dependent change in TEER over an extended culture period, 




The TEER was measured three times a week followed by a medium change. When a 
TEER of up to 1000 ·cm2 was reached, the cells were stimulated with 25 ng/ml TNF-
 and 30 ng/ml IFN-. The dotted line indicates the day of stimulation. The TEER was 
measured 24 and 48 hours after stimulation. n = 3 wells for the control group and n = 
3 wells for the stimulation group. 
 
  




Figure S8. Passage-dependent change in TEER over an extended culture period, 




The TEER was measured three times a week followed by a medium change. When a 
TEER of up to 1000 ·cm2 was reached, the cells were stimulated with 25 ng/ml TNF-
 and 30 ng/ml IFN-. The dotted line indicates the day of stimulation. The TEER was 
measured 24 and 48 hours after stimulation. n = 3 wells for the control group and n = 






The work presented in this thesis contributes to the development of an in vitro test strategy in 
order to reduce or to replace animal experiments for a safety assessment of orally inhaled drug 
products according to the Three Rs principle. It was demonstrated that a more complex exper-
imental structure does not necessarily lead to a better in vivo predictability of inflammatory 
reactions, not least because of missing data for a useful comparison. Consequently, at present, 
a step-by-step approach, which considers various aspects successively, is the most sensible tac-
tic for the realization of an in vitro safety assessment. The protocol for a safety assessment 
established in this thesis involves a) examining the cytotoxicity categorized by the IC50 value, 
and b) analysing the effects on inflammatory reactions on the epithelial barrier. Although this 
is a good starting point for a comprehensive test strategy, many issues which arose during this 
dissertation, remain to be investigated further to achieve a final regulatory acceptance. These 
include unanswered questions such as, how can we close the gap to the missing in vitro com-
parability of useful in vivo data; how important is the in vitro simulation of the complex physi-
ology of the lung and the exposure routes with corresponding deposition mechanisms to reach 
a better correlation; to what extent do non-cellular barriers play a role; and how can a standard-
ized in vitro test strategy be offered in the future, addressing all these issues obtained under 
`Good-Laboratory-Practice´ (GLP) according to the OECD GIVIMP1 guidelines. To address 
these challenges, some relevant aspects are discussed in more detail below. 
5.1 Complexity of an in vitro system has (still) no influence on an officially accepted alter-
native method 
In the first study, a complex experimental setup was chosen to achieve a physiological pollen 
deposition on the MucilAir™ system combined with the Dry powder chamber (VPC) of Vitro-
cell® systems. In addition, the protective and anti-inflammatory effect of an ointment formula-
tion was investigated via the release of IL-8 after bacterial lipopolysaccharides (LPS) stimula-
tion. An increased IL-8 release was obtained after 24 hours LPS simulation mimicking in vitro 
the human inflammation processes after an infection, but no verified in vitro - in vivo correlation 
(IVIVC) could be derived from these results. In 2019, Fizeşan et al. used a 3D tetraculture with 
Ea.hy 926, THP-1M, HMC-1 and A549 in combination with the Vitrocell™Cloud System to 
exposed silver particles and nanowires. With this setup, they were able to provide a near com-
plete overview of the particle exposition by analysing the cytotoxicity, RT-PCR of pro-inflam-
matory and stress response markers, characterisation of the exposed particles, ROS production, 





the pro-apoptotic gene CASP7 and the NFκB pathway were triggered after particle exposition,2 
which seems to simulate the in vivo situation for an inflammatory reaction.3 This very detailed 
study of Fizeşan et al. includes a data set larger than the data set obtained in the pollen exposure 
study performed in this dissertation, but they still could not provide any further information 
about a successful implementation of validation, standardization, or IVIVC. A year later, a 3D 
microfluidic lung-on-a-chip model of the alveolar epithelium (HPAEpiCs) co-cultivated with 
microvascular endothelium (HPMECs) was able to successfully simulate an increased release 
of inflammatory cytokines (IL-8, MCP-1, IL-1β, and TNF-α) after benzopyrene (BaP) exposi-
tion as an example of the human exposition to environmental pollution.4 Even these results 
from a more advanced microfluid device do not provide data that leads convincingly in the 
direction of a valid IVIVC. Overall, a lot of well performed studies leave some open questions 
due to a lack of an in vitro in vivo correlation. Here, the question arises why the development 
of pulmonary in vitro methods simulating the respiratory system is so far advanced but not able 
to correlate in vitro with in vivo.   
In 2015, Forbes et al. summarized several reasons for this still missing IVIVC. The main chal-
lenges are the in vitro simulation of aerosol deposition, absorption, dissolution, permeation and 
binding to the surrounding lung tissue and the resulting systemic availability, all of which are 
prerequisites for determining the effectiveness or toxicity of the inhaled substance.5 The in vivo 
analysis of deposited inhaled substance is performed, for example, with single-photon emission 
computed tomography (SPECT)6 or by pharmacokinetic and pharmacodynamic profiles.5,7 
However, not many in vitro studies are published which thematise the pharmacokinetic/dy-
namic investigations of the deposit substances in the lung. There are some in silico methods 
that combine, for example, computational fluid dynamics (CFD) and physiologically- based 
pharmacokinetic (PBPK) modelling, show promising success in predictability, but they must 
still be validated against in vivo results.8,9 Apart from the pharmacokinetic/dynamic issue, the 
comparison of the in vitro – in vivo dosimetry is still in discussion, especially regarding the 
cytotoxicity of nanomaterials.10 Addressing this issue , Loret et. al. used a compatible dose 
metrics system for the in vitro prediction of cytotoxicity of nanomaterials. Figure 1 shows the 
intersection of the dose metrics which should be used for the interpretation of in vitro (ALI, 
LLI) and in vivo (inhalation, instillation) to obtain a high predictability of their results. Never-
theless, Loret et al. were not able to establish a model by using the different dose metrics which 
increases the predictability for every type of in vitro deposition. The reasons for this were that 
data-sets did not provide exact dose intervals and only one type of relatively harmless nanopar-






Figure 1: Intersections of dose metrics of the in vitro methods (ALI, LLI) and in vivo deposition (inhalation 
and instillation).   
In the most cases, the doses of inhaled substance are expressed as mass/volume (mL) for LLI and instillation 
deposition, for ALI and inhalation mass/air volume (m³). For a better comparison of these different does metrics, 
the tissue surface, or the number of the cells (#/cells) and mass doses for the surface area (SA/cells) are the most 
suitable dose metric, especially for nanoparticles lung deposition. Adapted from Loret et al `Predicting the in vivo 
pulmonary toxicity induced by acute exposure to poorly soluble nanomaterials by using advanced in vitro meth-
ods´, copyright © 2018, The Author(s)12 
The aforementioned explanations demonstrate that even with a more complex experimental 
setup, such as described in the first study in this dissertation, no evidently improved in vivo 
predictability could be achieved. Therefore, a reduction of the complexity is required in order 
to continue with simple monolayers in a stepwise approach to evaluate first the cytotoxicity, 
and second, the inflammation reactions in vitro. One approach that specifically addresses a 
stepwise test strategy during a risk assessment is the framework of adverse outcome pathways 
(AOPs) connecting key events (KEs) and adverse outcomes (AOs) after a substance exposure 
which is also supported by the OECD.13 
5.2 An AOP-based approach is the most reliable way to perform an in vitro safety 
assessment 
Taking a closer look at the successful story of alternative methods for skin sensitization, we see 
that the OECD recommends several guidelines to confirm the incidence of a skin sensitisation 
potential of substances. The in vitro/in chemico guidelines TG 442C (Direct Peptide Reactivity 
Assay, DPRA) address the covalent binding to proteins as the first key event (KE1) of skin 





(ARENrf2 Luciferase test method) and the TG 442E describing the KE3 dendritic cell activa-
tion (h-CLAT, U-Sens™, IL-8 Luc assay).14–16 This breakdown in different KE under the ap-
plication of the AOP approach results in a diverse test strategy to rule out all possible conse-
quences of substance exposure. This stepwise approach applied for skin sensitization should be 
transferred to those AOPs necessary for a respiratory safety assessment. The specific AOPs are 
illustrated by Clippinger et al. as a result from a workshop of the PETA International Science 
Consortium Ltd., and the U.S. National Toxicology Program (NTP) Interagency Center for the 
Evaluation of Alternative Toxicological Methods (NICEATM) in 2018. As a result, the main 
respiratory AOs occurring after substance exposure are listed in the categories target site expo-
sure, molecular initiating key events (MIEs), tissue/organ KEs, and the organism/population 
KEs (Figure 2).17  
 
Figure 2: List of adverse outcomes (AOs) categorized in the related key events (KE) applying the adverse 
outcome pathway (AOP) approach after inhalation of materials which an in vitro test strategy should be 
able to simulate.   
The target site exposure (TSE) involves, inter alia, the circumstances of ADME properties, the chemical reactivity, 
and the physicochemical properties of the inhaled material. The molecular initiating event (MIE) is mainly char-
acterised by a potential receptor binding. After the signal enters the cell, different processes were triggered, such 
as the production of reactive oxygen species (ROS), cytokine release and protein modification. These events im-
pact the overall lung key event resulting mostly in diseases as alveolitis or bronchitis. The organism response leads 
to systemic toxicity effects and, in the worst case, to acute lethality. Adapted from Clippinger et al. Pathway-based 
predictive approaches for non-animal assessment of acute inhalation toxicity, © 2018 The Author(s). Published 
by Elsevier Ltd.17 
Part of the discussed AOPs are listed in the database ̀ AOP Wiki´ which is hosted by the Society 
for the Advancement of Adverse Outcome Pathways (SAAOP) under the guidance of the 





Applying the OECD advice for implementing the AOP framework in the development of guide-
lines,19 Vinken and Blaauboer discussed the cytotoxic effects of a chemical substance exposed 
to different cell lines in vitro. They proposed that the in vitro cytotoxicity should be evaluated 
by testing two assays related to two KEs. One KE is the mitochondrial damage which can be 
measured by a MTT assays to calculate the IC50 value.20 Following this interpretation, the 
categorization of various pharmaceutical excipients tested on lung epithelial cells proposed in 
this dissertation on the basis of the IC50 in the SAFE classification can be regarded as the 1st 
cellular KE in an AOP-based test strategy. To complete this KE of cytotoxicity, plasma mem-
brane damage should be examined as the second KE using a LDH assay.20 The AOP framework 
can also be used to some extent for the categorization of the 3rd study of this thesis, which deals 
with the consequences of inflammatory reactions on epithelial cells. According to Villeneuve 
et al. in 2018, the increased release of pro-inflammatory cytokines is one of the three KE in 
inflammation, next to the activation of tissue resident cells and leukocyte recruitment or acti-
vation, whereby the endpoint of the AOP is declared as lung fibrosis or emphysema.21 When 
trying to simulate the consequences of increased cytokine expression the question arises again 
of how to achieve the required complexity of the in vitro system. When studying inflammation 
process, different cell types, such as Th1/2 cells, macrophages (MDMs, MDCCs) and fibro-
blasts, are essential to reproduce the complete inflammatory AOP and should therefore be pre-
sent in the applied test stystem.21,22 In this dissertation, an external stimulation with cytokines 
on the respiratory epithelial hAELVi cells was performed successfully, which could cover an 
initial part of the discussed AOP by Villeneuve et al. as one AO in the KE of an increased 
cytokine presence of TNF-α/INF-γ.  
The stepwise approach of this dissertation also promotes the AOP framework. However, only 
two of countless KEs could be discussed partially. Further optimization and coordination are 
necessary to standardize more complex cell systems, for instance the microfluidic devices, 
which offer the possibility to cover concurrently several AOs resulting in an extensive and de-
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6 Conclusion and Perspectives 
The intention of this dissertation was to develop a test strategy for orally inhaled drug products 
employing the Three Rs principle. It was shown that more complex exposure systems combined 
with tissue-based cell systems, which simulate the lung physiology in an enhanced way, can be 
successfully implemented methodically. Nevertheless, no standardization or meaningful com-
parison with in vivo data could be obtained. For this reason, simpler cell systems were used in 
the studies conducted for this thesis to deal with separate adverse outcomes such as the cyto-
toxicity and, respectively, the inflammation effects of an inhaled substance. A successful cor-
relation with human data could be achieved through the SAFE classification, which will facili-
tate an initial in vitro assessment of the hazard potential of a substance. Furthermore, a simple 
test system was developed which enables the identification of potential pro- or anti-inflamma-
tory effects of substances on the epithelial barrier. Despite the successful establishment of sep-
arate methods to consider two relevant adverse outcomes, no uniform test strategy could be 
developed in this dissertation. Many challenges remain to be overcome on the way to an offi-
cially approved alternative method: 
1. A standardisation of cellular based in vitro assays is required for the official acceptance of 
an in vitro test strategy for orally inhaled drugs. According to the OECD GIVIMP guideline, a 
high-quality management for the development of an alternative method is necessary. Therefore, 
all methods, apparatus, utilities, chemicals, and data interpretation must be validated and ob-
tained under Good-Laboratory-Practice (GLP) conditions.  
2. To ensure the accuracy of the alternative method, an in vitro-in vivo correlation (IVIVC) 
must be performed. Regarding the IVIVC, a number of important issues have not been resolved, 
e.g., to what data sets can an in vitro result correlate with, for example, in vivo 
mouse/rat/dog/human? Where can the developer find these in vivo data sets? Here, a more trans-
parent policy of the agencies and the pharma industry is required.  
3. To submit an established in vitro test strategy to the competent authority, many bureaucratic 
challenges must be overcome without any financial compensation for the applicant. This is a 
lengthy and costly process that can only be carried out by a few larger companies. The ac-
ceptance criteria for a verification of an in vitro test system should be simplified so that research 
institutes or academic researchers with fewer financial resources can also contribute to the de-
velopment of alternative methods. 




Despite these challenges, the development of alternative methods for the respiratory safety as-
sessment is still being pushed forward, and with the combination of advanced in vitro and in 
silico methods, an overall picture of the substance effects can be obtained. A milestone in the 
next few years will probably be the evaluation and acceptance of the EpiAirway™ as an alter-
native method by the EURL ECVAM, which offers new opportunities for further developments. 
It should also be noted that public pressure can also contribute to the development of alternative 
methods, as it was shown on the example of the animal-free skin testing law. We need to ask 
ourselves to what extent are we prepared to accept reduced human safety in order to reduce 
animal experiments. And we must bear in mind that an in vitro model remains a model, or, to 
put it with René Magritte and his 1929 painting `La Trahison des images´:  
`The famous pipe. How people reproached me for it! And yet, could 
you stuff my pipe? No, it's just a representation, is it not? So if I 
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